Weil Advised Sanofi in its $3.2B Acquisition of Translate Bio
Weil advised Sanofi in its $3.2 billion acquisition of Translate Bio, Inc., a clinical-stage mRNA therapeutics company. The transaction closed on September 14, 2021.
The Weil team that advised Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associates Iliana Karaoglan, Daniel Sotsky and Emily Ross. The team also included Tax partner Graham Magill; Tax associate Charles Kogel; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits counsel Steven Margolis; Executive Compensation & Benefits associate Robin Caskey; Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions associates Lauren Springer, Maryann Thompson and Alex Theuer; Regulatory Transactions partner Shawn Cooley; Regulatory Transactions counsel John O’Loughlin; Regulatory Transactions associate Nathan Cunningham; Antitrust partner John Scribner; and Antitrust counsel Michael Naughton.
More from the Weil Tax Blog
Copyright © 2024 Weil, Gotshal & Manges LLP, All Rights Reserved. The contents of this website may contain attorney advertising under the laws of various states. Prior results do not guarantee a similar outcome. Weil, Gotshal & Manges LLP is headquartered in New York and has office locations in Boston, Brussels, Dallas, Frankfurt, Hong Kong, Houston, London, Miami, Munich, New York, Paris, Shanghai, Silicon Valley and Washington, D.C.